127 related articles for article (PubMed ID: 53656)
21. A low dose regime of 1 alpha hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study.
Cohen HN; Farrah D; Fogelman I; Goll CC; Beastall GH; McIntosh WB; Fletcher M; Boyle IT
Clin Endocrinol (Oxf); 1980 Jun; 12(6):537-42. PubMed ID: 7398099
[TBL] [Abstract][Full Text] [Related]
22. Biochemical effects of calcium supplementation in postmenopausal osteoporosis.
Horowitz M; Need AG; Morris HA; Wishart J; Nordin BE
Eur J Clin Nutr; 1988 Sep; 42(9):775-8. PubMed ID: 3181110
[TBL] [Abstract][Full Text] [Related]
23. Effect of sex hormones on bone in primary osteoporosis.
Riggs BL; Jowsey J; Kelly PJ; Jones JD; Maher FT
J Clin Invest; 1969 Jun; 48(6):1065-72. PubMed ID: 5771187
[TBL] [Abstract][Full Text] [Related]
24. Bone changes in rats with adjuvant arthritis: treatment with 1 alpha-hydroxycholecalciferol.
Binderup L
Acta Pharmacol Toxicol (Copenh); 1986 Sep; 59(3):228-35. PubMed ID: 3799201
[TBL] [Abstract][Full Text] [Related]
25. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.
Matloff DS; Kaplan MM; Neer RM; Goldberg MJ; Bitman W; Wolfe HJ
Gastroenterology; 1982 Jul; 83(1 Pt 1):97-102. PubMed ID: 7075948
[TBL] [Abstract][Full Text] [Related]
26. 99mTc-MDP retention in osteoporosis: relationship to other indices of bone cell activity and response to calcium and vitamin D therapy.
Davie MW; Britton JM; Haddaway M; McCall IW
Eur J Nucl Med; 1987; 13(9):462-6. PubMed ID: 3440471
[TBL] [Abstract][Full Text] [Related]
27. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
28. Effects of phosphorus supplementation on serum parathyroid hormone and bone morphology in osteoporosis.
Goldsmith RS; Jowsey J; Dubé WJ; Riggs BL; Arnaud CD; Kelly PJ
J Clin Endocrinol Metab; 1976 Sep; 43(3):523-32. PubMed ID: 956340
[TBL] [Abstract][Full Text] [Related]
29. Calcium metabolism and 47calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis.
Caniggia A; Gennari C; Bencini M; Cesari L; Borrello G
Clin Sci; 1970 Apr; 38(4):397-407. PubMed ID: 5428804
[No Abstract] [Full Text] [Related]
30. Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium.
Hoikka V; Alhava EM; Aro A; Karjalainen P; Rehnberg V
Acta Med Scand; 1980; 207(3):221-4. PubMed ID: 6989171
[TBL] [Abstract][Full Text] [Related]
31. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Kuntz D; Marie P; Berhel M; Caulin F
Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bone mineral loss in postmenopausal women by norethisterone.
Abdalla HI; Hart DM; Lindsay R; Leggate I; Hooke A
Obstet Gynecol; 1985 Dec; 66(6):789-92. PubMed ID: 4069480
[TBL] [Abstract][Full Text] [Related]
33. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
35. [Biological activity of 1alpha-hydroxycholecalciferol (1). Effect on intestine and bone in rats (author's transl)].
Kawashima H; Hoshina K; Saitoh N; Okamiya Y; Hashimoto Y; Ishimoto S; Noguchi T; Orimo H
Nihon Yakurigaku Zasshi; 1978 Mar; 74(2):267-83. PubMed ID: 658840
[TBL] [Abstract][Full Text] [Related]
36. The effect of supplemental oral phosphate on the bone mineral changes during prolonged bed rest.
Hulley SB; Vogel JM; Donaldson CL; Bayers JH; Friedman RJ; Rosen SN
J Clin Invest; 1971 Dec; 50(12):2506-18. PubMed ID: 5129304
[TBL] [Abstract][Full Text] [Related]
37. Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
Peacock M; Gallagher JC; Nordin BE
Lancet; 1974 Mar; 1(7854):385-89. PubMed ID: 4131034
[No Abstract] [Full Text] [Related]
38. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
[TBL] [Abstract][Full Text] [Related]
39. Transdermal estradiol in the treatment of postmenopausal bone loss.
Adami S; Suppi R; Bertoldo F; Rossini M; Residori M; Maresca V; Lo Cascio V
Bone Miner; 1989 Aug; 7(1):79-86. PubMed ID: 2670019
[TBL] [Abstract][Full Text] [Related]
40. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
